"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

The genomic medicine space has seen incredible success, but investors are overlooking it. For once, it’s not efficacy that’s ...

Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary ...

23andMe is currently trading at around $3.15, down from more than $18 at the start of the year and more than $200 on its ...

Mendelsohn – using history as a guide – suggests there will be a layering of new laws, with, for example, a push for changes ...

DXPs can now eliminate swivel chair processes. Commercial organisations can integrate existing systems with a DXP and have ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

Pelacarsen is in a cardiovascular outcomes trial in patients with elevated Lp (a) levels, with results expected in 2025, ...

In collaboration with AstraZeneca, Pfizer, Sanofi, and Ultragenyx, the 9th Commercializing Continuous Processing Summit ...

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy ...

US President-Elect Donald Trump is reported to be considering the nomination of Johns Hopkins surgeon and writer Martin Makary to lead the FDA after he takes office in January. The rumour was ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.